Why the study?
Do beta-blockers with intrinsic sympathomimetic activity offer a therapeutic advantage over pure beta antagonists in patients with ischaemic heart disease?
Do beta-blockers with intrinsic sympathomimetic activity offer a therapeutic advantage over pure beta antagonists in patients with ischaemic heart disease?
Beta-blockers with intrinsic sympathomimetic activity do not offer a clear therapeutic advantage over pure beta-blockers in ischaemic heart disease, and pure beta-blockers may be preferred in severe angina.
No takes yet. Share an insight, caveat, or question.
May favor pure beta antagonists for severe angina; leaves open need for RCTs confirming net benefit of ISA agents in ischaemic heart disease.
Northcote et al. (1985) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: